Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 3/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 6/20 | 0.41 |
| ▸ | MARK4 | Q96L34 | 4/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264282 | 0.87 | CDK4 (0.52) | FGFR1CCND3CCNA2CDK2MARK3 | |
| SCHEMBL4075363 | 0.85 | CDK4 (0.50) | EGFRFGFR1CCND3CCNA2CDK2 | |
| SCHEMBL29785344 | 0.78 | CYP2A6 (0.50) | PDE3BPDE3ACLK4KMT2ABTK | |
| SCHEMBL748173 | 0.77 | CCND3 (0.49) | ABL1CCND3CCNKCCNA2CDK2 | |
| SCHEMBL20400864 | 0.77 | SYK (0.51) | EGFRFGFR1ABL1CCND3MARK3 | |
| SCHEMBL29979953 | 0.74 | JAK1 (0.50) | AURKB | |
| SCHEMBL16416249 | 0.73 | MAPK8 (0.48) | EGFRFGFR1CCNKCCNA2CDK2 | |
| Acetic Acid SCHEMBL28058542 | 0.71 | CCND3 (0.44) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL16993339 | 0.70 | CDK4 (0.51) | EGFRFGFR1CCND3CCNA2CDK2 | |
| SCHEMBL17910166 | 0.70 | MAPK8 (0.54) | FGFR1ABL1CCND3CCNKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8518958-B2 | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Valo Health, LLC | 2011-08-18 | — | — | US | disclosed |
| EP-2084159-A1 | PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC Biotech Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008150260-A1 | 8-OXY-2-AMINOPYRIDO (2, 3-D) PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND ANTICANCER AGENTS | GPC BIOTECH, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008047307-A1 | PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC BIOTECH INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | disclosed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | CDK2, CDK4, CDK1 | EGFR 914/4885PNP 219/4885FGFR1 263/4885 |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | EGFR 816/4885PNP 89/4885FGFR1 745/4885 |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | DCK, PDXK, TK1 | EGFR 887/4885PNP 72/4885FGFR1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.